Barclays’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-113,303
| Closed | -$1.27M | – | 7344 |
|
|
2017
Q3 | $1.27M | Buy |
113,303
+28,348
| +33% | +$313K | ﹤0.01% | 2787 |
|
|
2017
Q2 | $934K | Buy |
84,955
+2,731
| +3% | +$27.3K | ﹤0.01% | 2947 |
|
|
2017
Q1 | $806K | Sell |
82,224
-59,906
| -42% | -$598K | ﹤0.01% | 2932 |
|
|
2016
Q4 | $1.53M | Buy |
142,130
+54,633
| +62% | +$546K | ﹤0.01% | 2354 |
|
|
2016
Q3 | $897K | Sell |
87,497
-3,965
| -4% | -$43.2K | ﹤0.01% | 2725 |
|
|
2016
Q2 | $1.19M | Buy |
91,462
+6,086
| +7% | +$79.7K | ﹤0.01% | 2457 |
|
|
2016
Q1 | $939K | Buy |
85,376
+60,822
| +248% | +$541K | ﹤0.01% | 2576 |
|
|
2015
Q4 | $221K | Sell |
24,554
-12,133
| -33% | -$102K | ﹤0.01% | 3831 |
|
|
2015
Q3 | $220K | Buy |
36,687
+35,680
| +3,543% | +$306K | ﹤0.01% | 4077 |
|
|
2015
Q2 | $10K | Sell |
1,007
-13,283
| -93% | -$121K | ﹤0.01% | 6112 |
|
|
2015
Q1 | $114K | Sell |
14,290
-3,369
| -19% | -$26.8K | ﹤0.01% | 4759 |
|
|
2014
Q4 | $141K | Buy |
17,659
+9,976
| +130% | +$80.8K | ﹤0.01% | 4912 |
|
|
2014
Q3 | $45K | Sell |
7,683
-24,495
| -76% | -$147K | ﹤0.01% | 5969 |
|
|
2014
Q2 | $161K | Sell |
32,178
-1,564
| -5% | -$7.61K | ﹤0.01% | 5021 |
|
|
2014
Q1 | $135K | Buy |
33,742
+20,467
| +154% | +$98.9K | ﹤0.01% | 5172 |
|
|
2013
Q4 | $66K | Sell |
13,275
-3,966
| -23% | -$19.1K | ﹤0.01% | 5992 |
|
|
2013
Q3 | $86K | Buy |
17,241
+6,617
| +62% | +$36.8K | ﹤0.01% | 5743 |
|
|
2013
Q2 | $53K | Buy |
+10,624
| New | +$50.6K | ﹤0.01% | 6270 |
|
Barclays's SCLN Position: Q4 2017 in Review
Barclays sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 113,303 shares — an estimated $1.27M sold.
Barclays first reported a position in SCLN in Q2 2013 and held it in 18 quarters. The position peaked at $1.53M in Q4 2016. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.
- Barclays reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
- Barclays sold 113,303 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $1.27M.
- Barclays first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and held it in 18 quarters.
- Barclays's Sciclone Pharmaceuticals Inc position peaked at $1.53M in Q4 2016.
- 0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.
Based on Barclays's 13F filing for Q4 2017, filed 14 Feb 2018.